Results 91 to 100 of about 146,874 (392)

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Health Technology Assessment, 2020
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tested in
Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn   +26 more
doaj   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

, 2014
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L., Goltsov, Alexey, Goltsov, Gregory, Harrison, David J., Langdon, Simon P.   +4 more
core   +4 more sources

Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer

Nature Communications, 2021
Trastuzumab is the backbone of HER2-directed gastric cancer therapy, but poor patient response due to insufficient cell sensitivity and drug resistance remains a clinical challenge.
W. Shi, Gengyuan Zhang, Zhijian Ma, Lianshun Li, Miaomiao Liu, Long Qin, Zeyuan Yu, Lei Zhao, Yang Liu, Xue Zhang, J. Qin, H. Ye, Xiangyan Jiang, Huinian Zhou, Hui Sun, Z. Jiao   +15 more
semanticscholar   +1 more source

Trastuzumab and cardiotoxicity

Libri Oncologici Croatian Journal of Oncology
Breast cancer survivors face an increased incidence of cardiac toxicities, which heightens their risk for cardiovascular disease compared to individuals without cancer, leading to poorer overall survival rates. Although trastuzumab has notably improved patient outcomes, its potential to induce cardiotoxicity has become a significant clinical concern ...
Sertić, Petra, Jakšić, Petra, Trajbar, Mihaela, Vazdar, Ljubica, Šeparović, Robert, Tečić-Vuger, Ana   +5 more
openaire   +3 more sources

An Ultrapotent, Ultraeconomical, Antifreeze Polypeptide

Advanced Materials, EarlyView.
Simple and inexpensive polypeptides composed of random copolymers of alanine and glutamic acid are effective antifreezes for applications in foods and biomedicine. The polypeptides, inspired by natural extremophile proteins, inhibit the growth of large ice crystals and prevent damage to sensitive biologics.
Thomas J. McPartlon, Charles T. Osborne, Ke Wang, Rachel E. Detwiler, Konrad Meister, Jessica R. Kramer   +5 more
wiley   +1 more source

Heterogeneity Landscape of Circulating Tumor Cells in Clinical Utility

Advanced Therapeutics, EarlyView.
This study reports the heterogeneity spectrum of circulating tumor cells. The factors involved in the spectrum promote CTCs to overcome barriers in the metastatic cascade but impact the clinical outcome of cancer patients. In summary, the heterogeneities in association with CTCs ultimately reduce patient survival and facilitate increasing mortality of ...
Md Kowsar Alam, Lu Yanjun, Bee Luan Khoo, Tongxu Si, Heng Zou, Mengsu Yang   +5 more
wiley   +1 more source

Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models. [PDF]

, 2015
We have previously developed mouse models of HER-2-positive cervical cancer. Tumors in nude mice had histological structures similar to the original tumor and were stained by anti-HER-2 antibody in the same pattern as the patient's cancer.
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Ichikawa, Yasushi, Maawy, Ali, Matsuyama, Ryusei, Mii, Sumiyuki, Miwa, Shinji, Momiyama, Masashi, Mori, Ryutaro, Murakami, Takashi, Tanaka, Kuniya, Uehara, Fuminari, Yamamoto, Mako, Yano, Shuya, Zhang, Nan, Zhang, Yong, Zhao, Ming   +19 more
core   +7 more sources

A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway

Journal of Hematology & Oncology, 2016
Background Trastuzumab, a humanized antibody targeting HER2, exhibits remarkable therapeutic efficacy against HER2-positive gastric cancer. However, recurrent therapeutic resistance presents revolutionary claims.
Jing Liu, Changqie Pan, Lihong Guo, Mengwan Wu, Jing Guo, Sheng Peng, Qianying Wu, Qiang Zuo   +7 more
doaj   +1 more source

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. [PDF]

PLoS ONE, 2012
OBJECTIVE: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial
Takehiro Ichikawa, Fumiaki Sato, Kazuya Terasawa, Soken Tsuchiya, Masakazu Toi, Gozoh Tsujimoto, Kazuharu Shimizu   +6 more
doaj   +1 more source

Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy [PDF]

, 2014
Background: After breast-conserving radiation therapy most patients experience acute skin toxicity to some degree. This may impair patients' quality of life, cause pain and discomfort. In this study, we investigated treatment and patient-related factors,
De Langhe, Sofie, De Neve, Wilfried, De Ruyck, Kim, DE SCHEPPER, ELINE, Gilsoul, Monique, MULLIEZ, THOMAS, Remouchamps, Vincent, Thierens, Hubert, van Greveling, Annick, Veldeman, Liv   +9 more
core   +2 more sources